Dr. Paul Goodyer, Professor of Pediatrics at McGill University and recognized leader in hereditary renal disease, is the principal investigator in the Phase 2 clinical trial On track to report top line data from Phase 2 clinical trials for ELX-02 in cystic fibrosis...
HCL Technologies (HCL), a leading global technology company and a Platinum-Level member of Oracle Partner Network (OPN), and Oracle Health Sciences today announced a collaboration to help life sciences companies execute and scale the next generation of digital...
Rafael Pharmaceuticals Inc.(“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today the launch of Rafael Trial Connect, a web portal available on the Company’s website that will serve as a resource to both...
– Potential to Accelerate Application of T-Cell Therapy to Other Solid Tumors Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel T-cell therapies that harness the evolutionary power of the immune system, today announced...
Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it received input from the U.S. Food and Drug Administration (FDA) on its End-of Phase 2 questions and has...
RegeneRx Biopharmaceuticals, Inc., (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today confirmed that the first patient enrolled in a...
Email
Text